Prosecution Insights
Last updated: October 02, 2026

Examiner: KLINKEL, KORTNEY L

Tech Center 3600 • Art Units: 1600 1611 1615 1625 1627 1699 3649

This examiner grants 40% of resolved cases

Analysis

Kortney L Klinkel is a patent examiner working in Tech Center 3600 and Art Unit 1600. This examiner has reached a final disposition in 598 resolved cases, which establishes the statistical foundation for their current prosecution metrics. These 598 resolved cases provide insight into the examiner's approach to patent applications within Art Unit 1600 and Tech Center 3600.

The data shows an allowance rate of 39.8 percent, reflecting the proportion of applications that are successfully granted. The median days to allowance for these cases is 1428. This duration of 1428 days represents the typical timeline for reaching a favorable outcome under this examiner's review. The 39.8 percent allowance rate suggests a challenging path to success for applications in this art unit.

The interview lift for this examiner is 43.1 percent. This 43.1 percent lift indicates that engaging in a direct dialogue with the examiner is associated with a significant increase in the probability of allowance compared to the baseline rate of 39.8 percent. Given the median days to allowance of 1428, the 43.1 percent interview lift offers a strategic opportunity for practitioners to potentially improve their results through active communication.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

39.8%
Allow Rate
-12.2% vs TC avg
608
Total Applications
+43.1%
Interview Lift
1428
Avg Prosecution Days
Based on 598 resolved cases, 2023–2026

Rejection Statute Breakdown

2.9%
§101 Eligibility
16.1%
§102 Novelty
36.0%
§103 Obviousness
25.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18664964 SMALL MOLECULE BTK DEGRADERS AND METHODS OF USE THEREOF Non-Final OA Baylor College of Medicine
18657004 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES Non-Final OA Takeda Pharmaceutical Company Limited
18361492 METHODS OF TREATING A CORONAVIRUS INFECTION Non-Final OA City of Hope
18355219 USE OF SMO INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING, DELAYING OR ALLEVIATING ACCESS STENOSIS OF ARTERIOVENOUS FISTULA Non-Final OA JINAN UNIVERSITY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month